Model for product development of vaccines against neglected tropical diseases: a vaccine against human hookworm.
This article provides an overview of the advances in product development and technology transfer of the vaccine against human hookworm, with particular emphasis on the lessons learned and the challenges of developing a vaccine in the nonprofit sector. The comprehensive approach to vaccine development established by the Human Hookworm Vaccine Initiative (HHVI) identifies key operational and technical aspects that are essential for a successful partnership with a developing country vaccine manufacturer. This article also highlights the importance of a global access roadmap to guide the vaccine development program. The advancement of new products for the control of neglected tropical diseases portends great challenges for global access, including aspects related to vaccine design, product development and manufacture, vaccine introduction and distribution, financing, knowledge dissemination and intellectual property management. With only three vaccines for neglected tropical diseases in clinical trials - hookworm, leishmaniasis and schistosomiasis - we are at the nascent stages of developing vaccines for neglected populations. Product development public-private partnerships, such as the HHVI, continue to show great promise on this front and will eventually provide significant control tools for achieving millennium development goals related to poverty reduction, as well as child and maternal health.
Bottazzi
Maria Elena
ME
Department of Microbiology, Immunology and Tropical Medicine, The George Washington University, 2300 Eye Street NW, Ross Hall, Washington, DC 20037, USA. mtmmeb@gwumc.edu
Brown
Ami Shah
AS
D000723:Ancylostomatoidea / Q000276:immunology*; D000818:Animals; D006725:Hookworm Infections / Q000453:epidemiology / Q000517:prevention & control*; D006801:Humans; D012106:Research; D014612:Vaccines / Q000276:immunology*
D014612:Vaccines